Business
AlloVir Reports Full-Year 2021 Financial Results and 2022 Outlook
Three ongoing Phase 3 registrational studies of posoleucel expected in 2022, targeting treatment and prevention indications with no approved therapies
About this update from Kalaris Therapeutics, Inc.
[{"type":"text","content":"\nThree ongoing Phase 3 registrational studies of posoleucel expected in 2022, targeting treatment and prevention indications with no approved therapies\n\nExpanded enrollment in Phase 2 proof-of-concept study of posoleucel for the preemptive treatment of BK viremia in kidney transplant recipients; initial data submitted for presentation in 1H 2022\n\nAdvancing two additional virus-specific T cell therapies – ALVR106 to treat common respiratory viral infections and ALVR107 for hepatitis B cure\n\nStrong cash position, with $248.1 million as of year-end 2021\n\n WALTHAM, Mass.--(BUSINESS WIRE)--\nAlloVir (Nasdaq: ALVR), a late clinical-stage allogeneic T cell immunotherapy company, today reported full-year 2021 financial results for the period ended December 31, 2021. The company also provided the outlook for 2022 across its pipeline of allogeneic, off-the-shelf, virus-specific T cell (VST) therapies for immunocompromised patients, including its lead product posoleucel, an investigational VST in development for the treatment and prevention of infections and diseases caused by six common devastating viruses – adenovirus (AdV), BK virus (BKV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), human herpesvirus-6 (HHV-6) and JC virus (JCV).\n\n“2022 is a year of execution and expansion for our clinical development program, as we implement three Phase 3 registrational studies across sites in North America, Europe and Asia, present new data that expand on posoleucel’s potential in both the treatment and prevention of six life-threatening viruses, and continue to advance two additional VST therapies,” said Diana Brainard, M.D., Chief Executive Officer of AlloVir. “Beyond our clinical development programs, we are also advancing the manufacturing of posoleucel in anticipation of commercial product requirements and global distribution. Our non-gene-edited VST manufacturing platform is commercially scalable and can achieve cost of goods similar to biologics. This positions us well for the next stage of our company’s growth as our pipeline continues to mature.”\n\nRecent Highlights\n\n\nAdvancing Posoleucel Development\n\n\nAt the American Society of Hematology (ASH) Annual Meeting in December 2021, AlloVir reported positive preliminary data from the open-label Phase 2 study assessing the safety and efficacy of posoleucel for the prevention ...